|
US2020271668A1
|
|
Methods for diagnosing and treating eosinophilic gastritis
|
|
WO2020172432A1
|
|
Methods and compositions for the detection, classification, and diagnosis of chronic post-surgical pain
|
|
WO2020101828A2
|
|
Modular expression systems for gene expression and methods of using same
|
|
US2020270242A1
|
|
Compounds, compositions, methods for treating diseases, and methods for preparing compounds
|
|
US2018015075A1
|
|
Methods and compositions for treatment of venous malformation
|
|
US2018016314A1
|
|
Treatment of disease via transcription factor modulation
|
|
US2017326155A1
|
|
Novel pharmacological therapy for neuromuscular contractures
|
|
US2017319651A1
|
|
Pharmacological therapy for neuronopathic Gaucher disease
|
|
US2017266319A1
|
|
Methods and compositions for treating conditions associated with spinal cord injury
|
|
WO2017075054A1
|
|
Methods and compositions for the treatment of head and neck cancer
|
|
US2017105982A1
|
|
Compositions and methods for treatment of lung dysfunction
|
|
WO2017008046A1
|
|
Loss of transcriptional fidelity leads to immunotherapy resistance in cancers
|
|
WO2016200627A1
|
|
Dosing algorithm for complement inhibitor
|
|
WO2016196070A1
|
|
Compositions and methods for treating neonatal biliary atresia
|
|
CA2980748A1
|
|
Use of kit inhibitors to condition subjects for a hematopoietic stem cell (hsc) transplantation
|
|
US2016235295A1
|
|
Quantitative pupillometry as a bedside predictor of postoperative respiratory depression
|
|
US2016257972A1
|
|
Foamy viral vector compositions and methods for the manufacture of same
|
|
US2018022810A1
|
|
Use of cxcr3 inhibitors for protecting against fetal wastage
|
|
US2016199373A1
|
|
Compositions and methods for treatment of fragile X syndrome
|
|
US2016129012A1
|
|
Compositions and methods for treating allergic inflammation through inhibition of NTRK1
|
